A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results.

Rockstroh, Jürgen K

A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. [electronic resource] - Journal of acquired immune deficiency syndromes (1999) Apr 2013 - 483-6 p. digital

Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1944-7884

10.1097/QAI.0b013e318286415c doi


Adenine--analogs & derivatives
Adult
Alanine Transaminase--blood
Anti-HIV Agents--therapeutic use
Aspartate Aminotransferases--blood
Atazanavir Sulfate
Bilirubin--blood
Bone Density--drug effects
Carbamates--therapeutic use
Cobicistat
Confidence Intervals
Creatinine--blood
Deoxycytidine--analogs & derivatives
Double-Blind Method
Drug Combinations
Emtricitabine
Female
HIV Infections--blood
HIV-1--genetics
Humans
Male
Oligopeptides--therapeutic use
Organophosphonates--therapeutic use
Pyridines--therapeutic use
Quinolones--therapeutic use
RNA, Viral--blood
Ritonavir--therapeutic use
Tenofovir
Thiazoles--therapeutic use
Triglycerides--blood